Abstract
Alzheimers disease (AD) is the most common neurodegenerative disease in the developed world. The increasing life expectancy in the last years has led to an increase in the prevalence of this age-related condition and has posed an important medical and social challenge for developed societies. The mainstays of current therapy for AD rely on the cholinergic hypothesis developed more than 20 years ago. These compounds, known as acetylcholinesterase inhibitors (AChEIs), inhibit the cholinesterases and aim at improving the brain synaptic availability of acetylcholine. These drugs have been approved for the treatment of AD based on pivotal clinical trials showing modest symptomatic benefit on cognitive, behavioral, and global measures. Memantine, an NMDA antagonist, has been recently included as a therapeutic option for AD. Memantine can be combined safely with AChEIs for an additional symptomatic benefit. During the last years our understanding of the mechanisms underlying the pathogenesis of AD has markedly expanded. Several putative neuroprotective drugs are thoroughly investigated and many of them have reached the clinical arena. It can be anticipated that some of these drugs will be able to slow/prevent the progression of this condition in the near future.
Keywords: Treatment, Alzheimer's, acetylcholinesterase inhibitors, memantine, amyloid, behavioral symptoms, vitamin E, anti-inflammatory drugs
Current Genomics
Title: Current Therapeutic Options for Alzheimers Disease
Volume: 8 Issue: 8
Author(s): Alberto Lleo
Affiliation:
Keywords: Treatment, Alzheimer's, acetylcholinesterase inhibitors, memantine, amyloid, behavioral symptoms, vitamin E, anti-inflammatory drugs
Abstract: Alzheimers disease (AD) is the most common neurodegenerative disease in the developed world. The increasing life expectancy in the last years has led to an increase in the prevalence of this age-related condition and has posed an important medical and social challenge for developed societies. The mainstays of current therapy for AD rely on the cholinergic hypothesis developed more than 20 years ago. These compounds, known as acetylcholinesterase inhibitors (AChEIs), inhibit the cholinesterases and aim at improving the brain synaptic availability of acetylcholine. These drugs have been approved for the treatment of AD based on pivotal clinical trials showing modest symptomatic benefit on cognitive, behavioral, and global measures. Memantine, an NMDA antagonist, has been recently included as a therapeutic option for AD. Memantine can be combined safely with AChEIs for an additional symptomatic benefit. During the last years our understanding of the mechanisms underlying the pathogenesis of AD has markedly expanded. Several putative neuroprotective drugs are thoroughly investigated and many of them have reached the clinical arena. It can be anticipated that some of these drugs will be able to slow/prevent the progression of this condition in the near future.
Export Options
About this article
Cite this article as:
Lleo Alberto, Current Therapeutic Options for Alzheimers Disease, Current Genomics 2007; 8 (8) . https://dx.doi.org/10.2174/138920207783769549
DOI https://dx.doi.org/10.2174/138920207783769549 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pre-attentive Visual Processing in Alzheimer’s Disease: An Event-related Potential Study
Current Alzheimer Research Recent Developments in the Separation of Low Molecular Weight Heparin Anticoagulants
Current Medicinal Chemistry Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Association of Neutrophil-Lymphocyte Ratio with Mild Cognitive Impairment in Elderly Chinese Adults: A Case-control Study
Current Alzheimer Research Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Hyperhomocysteinemia, Pteridines and Oxidative Stress
Current Drug Metabolism A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Applications of Chemical Shift Imaging for AD
Current Medical Imaging Density Functional Theory, Molecular Interaction Fields, Pharmacophore, Virtual Screening and Physical Chemistry of the Interactions of Novel Acetylcholinesterase Inhibitors in Alzheimer´s Disease
Current Physical Chemistry CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Current Alzheimer Research Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review
Current Topics in Medicinal Chemistry The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in Alzheimer´s Disease
Current Alzheimer Research Comparative Effectiveness of Agmatine and Choline Treatment in Rats with Cognitive Impairment Induced by AlCl<sub>3</sub> and Forced Swim Stress
Current Clinical Pharmacology Effects of the KIBRA Single Nucleotide Polymorphism on Synaptic Plasticity and Memory: A Review of the Literature
Current Neuropharmacology Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Current Pharmaceutical Design